166 results
8-K
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
decide to shorten the Revised Exercise Period. Ms. Piccina will also be entitled to additional employee benefits.
The Company may terminate Ms. Piccina’s
8-K
EX-10.1
kded5346pm9wpzd5w1
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
rt7 ankyxn
30 Nov 23
Registration of securities for employees
4:16pm
S-8
eatsgq01qqs6u8yd5kov
30 Nov 23
Registration of securities for employees
4:16pm
S-8
EX-5.1
xa5fbvocgfde80
30 Nov 23
Registration of securities for employees
4:16pm
S-8 POS
ft4xnn
29 Jun 23
Registration of securities for employees (post-effective amendment)
4:54pm
S-8 POS
eytq9 t54z7cw86nkc3c
29 Jun 23
Registration of securities for employees (post-effective amendment)
4:48pm
8-K
EX-10.2
7gx 2labjaqqmoqbpo
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
1h3itv t3grxvo6h4di
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
xgdd7m 17x2
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
7vt6fynu
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
r2me0zmp
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
vj4aapq6
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
l71j9b4nrbu9jx419yb
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm